Cardiorenal Risk Stratification Pilot Study

NCT03628443 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-10-16

No results posted yet for this study

Summary

This is prospective cohort study with the purpose of improving our understanding of morbidity and mortality risk in patients with heart failure and chronic kidney disease.

Conditions

Interventions

DIAGNOSTIC_TEST

Fibroblast Growth Factor 23

A sample of blood is tested for levels of fibroblast growth factor 23

Sponsors & Collaborators

  • Coney Island Hospital, Brooklyn, NY

    lead OTHER

Principal Investigators

  • George Juang, MD · Coney Island Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-19
Primary Completion
2019-10-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03628443 on ClinicalTrials.gov